שם החברה: Hadasit Medical Research Services & Development Ltd.

שנת ייסוד: 1986

מספר עובדים: 10

סקטור: Life sciences

תת סקטור: Biotechnology

---

 

פרופיל חברה

Our Mission

Hadasit’s mission is to promote and commercialize the vast intellectual property and R&D capabilities generated at Hadassah on an ongoing basis, either through product licensing or by establishing start-up companies under the auspices of Hadassah or Hadasit Bio-Holdings Ltd. (TASE:HDST).

Our Achievements

Hadasit has gained global recognition for successfully enterprising biomedical technologies developed at Hadassah. We currently boast a rich portfolio of over 400 patent families covering a wide variety of novel therapeutics, diagnostics and medical devices. Of the more than 30 companies established by Hadasit, nine are currently operating under the publicly-traded Hadasit Bio-Holdings. In addition, dozens of research and license option agreements are in place with global strategic partners.

Our Activities

Promoting Investments – Hadasit’s key activity, as facilitator and partner, is to seek life-science investors – private, institutional, and corporate – for innovative biomedical technologies originating at Hadassah.

Consulting – Tapping into the wealth of knowledge at Hadassah, we also provide consulting services to entrepreneurs, investors, and life science companies via our medical and scientific experts from the entire range of therapeutic and diagnostic specialties.

Contracting Clinical Trials – Over 200 clinical trials were conducted at Hadassah during 2008 by pharma, device, and biotech companies from across the globe. With a seasoned clinical staff and a proven track-record, this prestigious teaching hospital set in a unique clinical arena of 2 academic hospitals with1100 beds and an annual turnover of 100,000 inpatients and 1,000,000 outpatient visits is a frequent choice for companies seeking the highest standards. Hadasit handles the contractual aspects of all clinical trials conducted at Hadassah.

Our Resources

The Hadassah Clinical Research Center (HCRC) is a GCP-compliant, 15-bed unit located in the Hadassah-Hebrew University BioPark, offering pharma, device, and biotech companies a complete package of services and facilities for conducting Phase I and II clinical trials. The HCRC is a joint venture of Hadasit and the Clinical Pharmacology Unit in the Division of Medicine. Prof. Yoseph Caraco, a clinical pharmacologist with a world-wide reputation in research leads a team consisting of an additional clinical pharmacologist, research dedicated nurses, study coordinators and a pharmacist, all trained to conduct research with the highest international standards.

The HCRC is particularly focused on adherence to schedule by expediting patient enrollment, IRB approval, and the availability of essential clinical experts. This, combined with an experienced research team, a large and diverse patient pool, access to a cost-effective GMP facility, and rigorous IRB standards, makes the HCRC an ideal choice. In addition, pre-clinical, Phase III and Phase IV studies can be conducted at the various Hadassah facilities.

The Hadassah-Medical Center Hebrew University Biotechnology Park (JBP) is located in the heart of Ein Kerem Hadassah medical campus in Jerusalem.

The JBP is a state of the art customized facility, tailored to the needs of biotech companies. Companies will benefit from close proximity to the rich infrastructure and extensive facilities of the Hebrew University schools of medicine, dentistry, pharmacy, nursing and public health, and the Hadassah University Hospital.

This nearness fosters synergistic partnership and meets the needs of early stage companies, large companies, multi-national life science companies, growing firms, and the related institutional research facilities, all who share the goal of developing therapeutic life science technologies. JBP will serve as a catalyst to transform Jerusalem from a scientific research hub to an economic engine for bioscience technologies.